Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure.
D000617:Aminoglycosides / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000096:biosynthesis; D015214:Antigens, Differentiation, Myelomonocytic / Q000096:biosynthesis; D002648:Child; D002675:Child, Preschool; D005260:Female; D000079982:Gemtuzumab; D018380:Hematopoietic Stem Cell Transplantation; D006504:Hepatic Veno-Occlusive Disease / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011089:Polydeoxyribonucleotides / Q000494:pharmacology*; D012008:Recurrence; D012044:Regression Analysis; D012074:Remission Induction; D063268:Sialic Acid Binding Ig-like Lectin 3
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D010975:Platelet Aggregation Inhibitors; D011089:Polydeoxyribonucleotides; D063268:Sialic Acid Binding Ig-like Lectin 3; C036901:defibrotide; D000079982:Gemtuzumab